Skip to main content

The AHRQ National Quality Measures Clearinghouse (NQMC, qualitymeasures.ahrq.gov) Web site will not be available after July 16, 2018 because federal funding
through AHRQ will no longer be available to support the NQMC as of that date. For additional information, read our full announcement.
  • Measure Summary
  • NQMC:011242
  • Feb 2017

Lung cancer: proportion of patients with lung cancer who receive active treatment who die within 30 days of treatment.

NHS Scotland, Scottish Cancer Taskforce, National Cancer Quality Steering Group. Lung cancer clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2017 Feb. 37 p. [13 references]

View the original measure documentation External Web Site Policy

This is the current release of the measure.

Primary Measure Domain

Clinical Quality Measures: Outcome

Secondary Measure Domain

Does not apply to this measure

Description

This measure is used to assess the proportion of patients with lung cancer who receive active treatment who die within 30 days of treatment.

This indicator will be split by diagnosis of non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) for palliative chemotherapy and biological therapy.

This Cancer Quality Performance Indicator (QPI) is separated into two parts. Please refer to the related NQMC measure summary, Lung cancer: proportion of patients with lung cancer who receive treatment with curative intent (surgery, radical radiotherapy or chemoradiotherapy) who die within 90 days of treatment.

Note from the National Quality Measures Clearinghouse: This measure is part of the QPIs collection. For more information, including a complete list of QPI measure sets, please visit the Healthcare Improvement Scotland Web site External Web Site Policy.

Rationale

Treatment related mortality is a marker of the quality and safety of the whole service provided by the multidisciplinary team (MDT) (NHS Quality Improvement Scotland, 2008). Outcomes of treatment, including treatment related morbidity and mortality should be regularly assessed.

Treatment should only be undertaken in individuals that may benefit from that treatment, that is, treatments should not be undertaken in futile situations. This Cancer Quality Performance Indicator (QPI) is intended to ensure treatment is given appropriately, and the outcome reported on and reviewed.

Note: Systemic therapy is treatment received for initial management and not treatment for recurrence or relapse.

Evidence for Rationale

NHS Quality Improvement Scotland. Management of lung cancer services. Edinburgh (Scotland): NHS Quality Improvement Scotland; 2008 Jul. 29 p.

NHS Scotland, Scottish Cancer Taskforce, National Cancer Quality Steering Group. Lung cancer clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2017 Feb. 37 p. [13 references]

Primary Health Components

Lung cancer; active treatment; death

Denominator Description

All patients with lung cancer who receive active treatment (see the related "Denominator Inclusions/Exclusions" field)

Numerator Description

Number of patients with lung cancer who receive active treatment who die within 30 days of treatment (see the related "Numerator Inclusions/Exclusions" field)

Type of Evidence Supporting the Criterion of Quality for the Measure

  • A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
  • A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences

Additional Information Supporting Need for the Measure

Unspecified

Extent of Measure Testing

The collection of data is piloted on a small number of patient records using a paper data collection form produced by Information Services Division (ISD). The aim is to identify any anomalies or difficulties with data collection prior to full implementation. At least one NHS board in each Regional Cancer Network participates in the pilot.

Evidence for Extent of Measure Testing

NHS Scotland. National cancer quality performance indicators: overview of development process. Edinburgh (Scotland): NHS Scotland; 2012 Dec. 7 p.

State of Use

Current routine use

Current Use

Internal quality improvement

National reporting

Public reporting

Measurement Setting

Ambulatory/Office-based Care

Ambulatory Procedure/Imaging Center

Hospital Inpatient

Hospital Outpatient

Professionals Involved in Delivery of Health Services

Physicians

Least Aggregated Level of Services Delivery Addressed

Single Health Care Delivery or Public Health Organizations

Statement of Acceptable Minimum Sample Size

Unspecified

Target Population Age

Unspecified

Target Population Gender

Either male or female

National Quality Strategy Aim

Better Care

National Quality Strategy Priority

Making Care Safer
Prevention and Treatment of Leading Causes of Mortality

IOM Care Need

Living with Illness

IOM Domain

Effectiveness

Safety

Case Finding Period

Unspecified

Denominator Sampling Frame

Patients associated with provider

Denominator (Index) Event or Characteristic

Clinical Condition

Therapeutic Intervention

Denominator Time Window

Does not apply to this measure

Denominator Inclusions/Exclusions

Inclusions
All patients with lung cancer who receive active treatment

Active treatment includes:

  • Surgery
  • Radical radiotherapy (greater than or equal to 54Gy)
  • Adjuvant chemotherapy
  • Chemoradiotherapy
  • Palliative chemotherapy

Exclusions
None

Exclusions/Exceptions

None

Numerator Inclusions/Exclusions

Inclusions
Number of patients with lung cancer who receive active treatment who die within 30 days of treatment

Note: This indicator will be split by diagnosis of non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) for palliative chemotherapy and biological therapy.

Exclusions
None

Numerator Search Strategy

Fixed time period or point in time

Data Source

Electronic health/medical record

Paper medical record

Type of Health State

Death

Instruments Used and/or Associated with the Measure

Unspecified

Measure Specifies Disaggregation

Measure is disaggregated into categories based on different definitions of the denominator and/or numerator

Basis for Disaggregation

This indicator will be split by diagnosis of non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) for palliative chemotherapy and biological therapy.

Scoring

Rate/Proportion

Interpretation of Score

Desired value is a lower score

Allowance for Patient or Population Factors

Unspecified

Standard of Comparison

External comparison at a point in, or interval of, time

External comparison of time trends

Internal time comparison

Prescriptive standard

Prescriptive Standard

Targets:

  • Surgery, Radical Radiotherapy, Adjuvant Chemotherapy and Radical Chemoradiotherapy – less than 5%
  • Palliative Chemotherapy/Biological Therapy
    • Non small cell lung cancer (NSCLC) – less than 10%
    • Small cell lung cancer (SCLC) – less than 15%

Evidence for Prescriptive Standard

NHS Scotland, Scottish Cancer Taskforce, National Cancer Quality Steering Group. Lung cancer clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2017 Feb. 37 p. [13 references]

Original Title

QPI 13 (i) – mortality following treatment for lung cancer.

Measure Collection Name

Cancer Quality Performance Indicators (QPIs)

Measure Set Name

Lung Cancer

Submitter

NHS Scotland - National Government Agency [Non-U.S.]

Scottish Cancer Taskforce - National Government Agency [Non-U.S.]

Developer

NHS Scotland - National Government Agency [Non-U.S.]

Scottish Cancer Taskforce - National Government Agency [Non-U.S.]

Funding Source(s)

Scottish Government

Composition of the Group that Developed the Measure

Lung Cancer QPI Development Group

Financial Disclosures/Other Potential Conflicts of Interest

Unspecified

Adaptation

This measure was not adapted from another source.

Date of Most Current Version in NQMC

2017 Feb

Measure Maintenance

The Cancer Quality Performance Indicators (QPIs) will be kept under regular review and be responsive to changes in clinical practice and emerging evidence.

Date of Next Anticipated Revision

Unspecified

Measure Status

This is the current release of the measure.

Source(s)

NHS Scotland, Scottish Cancer Taskforce, National Cancer Quality Steering Group. Lung cancer clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2017 Feb. 37 p. [13 references]

Measure Availability

Source document available from the Healthcare Improvement Scotland Web site External Web Site Policy.

For more information, contact the Healthcare Improvement Scotland at Gyle Square, 1 South Gyle Crescent, Edinburgh, Scotland EH12 9EB; Phone: 0131 623 4300; E-mail: comments.his@nhs.net; Web site: www.healthcareimprovementscotland.org/ External Web Site Policy.

Companion Documents

The following is available:

  • NHS Scotland. National cancer quality performance indicators: overview of development process. Edinburgh (Scotland): NHS Scotland; 2012 Dec. 7 p. This document is available from the Healthcare Improvement Scotland Web site External Web Site Policy.

NQMC Status

This NQMC summary was completed by ECRI Institute on June 14, 2017.

Copyright Statement

No copyright restrictions apply.

NQMC Disclaimer

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

About NQMC Measure Summaries

NQMC provides structured summaries containing information about measures and their development.

Measure Summary FAQs


Measure Summaries

New This Week

View more and sign up for our Newsletter

Get Adobe Reader